Status: Not yet recruiting
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
To evaluate the efficacy and safety of immune checkpoint inhibitor-based combination therapy with targeted therapy and chemotherapy in patients with locally advanced unresectable or metastatic colorectal cancer.
Participants needed: 42
Trial details
Phase: Phase 4Age: 18-75Biological sex: AllType: InterventionalSponsor: Ye XuUpdated: Mar 3, 2026Locations: 1
Eligibility criteria
Age 18-75 years; [+9]
Prior immune checkpoint inhibitor therapy; [+7]